Herpes zoster vaccination pocket guide for immunizers

Herpes Zoster Vaccines

- 1. Live attenuated zoster vaccine (LZV)
- 2. Recombinant zoster vaccine (RZV)

Recommendations for use

The National Advisory Committee on Immunization¹ recommends:

- Vaccination of individuals 50 years of age and older without contraindications with RZV
- Vaccination of individuals 50 years of age and older without contraindications with RZV if they received the LZV or had an episode of herpes zoster
- If RZV is contraindicated, unavailable or inaccessible, then LZV may be considered for immunocompetent individuals 50 years of age and older without contraindications
- RZV (not LZV) may be considered for immunocompromised adults 50 years of age and older

Dosage and Schedule

1. Live attenuated zoster vaccine (LZV)

- · Single-dose regimen of 0.65mL given by subcutaneous injection
- Recombinant zoster vaccine (RZV)
 - Two doses of 0.5mL given intramuscularly into the deltoid region of the upper arm at 2 to 6 months apart
 - A 0 and 12 months schedule may be considered for improved adherence to second dose

Contraindications and Precautions

- Both LZV and RZV are contraindicated in persons with a history of anaphylaxis after previous administration of the vaccine.
- · Since LZV is a live vaccine, it is contraindicated in:
 - individuals with primary and acquired immunocompromised states
 - individuals who have recently used or are currently using immune-suppressive medications
 - · active untreated tuberculosis
 - pregnancy pregnancy should also be avoided for three months after the administration of the vaccine

Adverse Events Associated with Either Vaccine

erythema

- fatigue
- pain at injection site
- myalgia

· headache

pain at injection site • myaig

Simultaneous Administration with Other Vaccines

- RZV and LZV may be administered concomitantly with other live vaccines given by parenteral, oral or intranasal routes.
- Inactivated vaccines, including RZV, may be administered concomitantly with, or at any time before or after, other inactivated vaccines or live vaccines protecting against a different disease.
- LZV may be given at any time before or after live oral or intranasal vaccines. If two live parenteral vaccines are not administered concomitantly, there should be a period of at least 4 weeks before the second live parenteral vaccine is given.

Duration of Protection

- While protection against HZ remains statistically significant up to 3 years following immunization with LZV, significant waning of protection has been observed one-year post immunization, particularly in older age groups.
- LZV vaccine may not provide optimal ongoing protection at older ages, and waning of vaccine efficacy against PHN over time is unknown.
- Waning of protection against herpes zoster appears to occur at a slower rate with RZV compared to LZV, and is minimal for at least 4 years post-immunization.

Counseling Points

Patient education on the short-term reactogenicity of RZV is recommended before the vaccine is administered, to promote adherence to the second dose.

Reference

National Advisory Committee on Immunization (NACI). Updated Recommendations on the Use of Herpes Zoster Vaccines (2018). An Advisory Committee Statement (ACS). https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html



